The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Behçet’s disease and uveitis

Authors:

Razumova I.Yu., Godzenko A.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(5): 130‑137

DOI: 10.17116/oftalma2021137051130

Read: 7620 times

Download PDF (RU)
Contact the author
Table of contents

BEHÇET’S DISEASE AND UVEITIS
BEHÇET’S DISEASE AND UVEITIS

To cite this article:

Razumova IYu, Godzenko AA. Behçet’s disease and uveitis. Russian Annals of Ophthalmology. 2021;137(5):130‑137. (In Russ.)
https://doi.org/10.17116/oftalma2021137051130

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Biomarkers in tear fluid in uveitis. Russian Annals of Ophthalmology. 2025;(4):88-95
Challenges of differential diagnosis in the veri­fication of Behçet’s disease with neurological mani­festations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):108-113
Infi­ltrative-ulcerative lesion of the larynx in Behcet’s disease. Russian Bulletin of Otorhinolaryngology. 2025;(4):112-114
Abstract:

This literature review is dedicated to the Behçet’s disease — a multi-symptom, severe autoimmune condition, relatively rare among the population of the former Soviet republics, and to one of its three most frequent manifestations — uveitis.

Keywords:

Behçet’s disease
uveitis

Authors:

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Received:

10.11.2020

Accepted:

23.12.2020

Close metadata

References:

  1. Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behcet’s disease physiopathology: a contemporary review. Auto Immun Highlights. 2016;7(1):4.  https://doi.org/10.1007/s 13317-016-0074-7
  2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Cross WL, Guillevin L, Yagen ES, Garrido M, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.  https://doi.org/10.1002/art/37715
  3. Hatemi G, Christensen R, Bang D, Bodaghi B, Celic AF, Fortune F, Gaudric J, Gul A, Kotter I. 2018 update of the EULAR recommendation for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77:808-818.  https://doi.org/10.1036/annrheumdis-2018-23225
  4. Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, et al. Behcet’s disease: epidemiology, ethiology and clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017; 13(1):57-65.  https://doi.org/10.1080/1744666X.2016.1205486
  5. Hatemi G, Seyahi E, Fresko I, Talarico R, Yamuryudan V. One year in review Behcet’s syndrome. Clin Exp Rheumatol. 2016;34(6 suppl 102):10-22. 
  6. Lehner T. The role of heat shock protein, microbial and autoimmune agent in the etiology of Behcet’s disease. Int Rev Immunol. 1997;14(1):21-32.  https://doi.org/10.3109/08830189709116842
  7. Matzinger P. The danger model: a renewed sense of self. Science. 2002; 296(5566):301-305.  https://doi.org/10.1126/science. 1071059
  8. Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, et al. Behcet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):369-376.  https://doi.org/10.1016/j/autrev.2014.11.009
  9. Goloeva RG, Alekberova ZS, Guseva IA, Krilov MYu. Behcet”s disease and association with antigen HLA-B5 (review of literature and own data). Terapevticheskii arkhiv. 2010;(5):45-50 (In Russ.).
  10. Mc Gonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H. MHC-1-opathy-unified concept for spondyloarthritis and Behcet’s disease. Nat Rev Rheumatol. 2015;11(12):731-740.  https://doi.org/10.1038/nrrheum. 2015.147
  11. Razumova IYu, Godzenko AA, Guseva IA, Vorob’eva OK. Uveitis-associated HLA class 1 histocompatibility antigens. Vestnik oftalmologii. 2017;133(5): 11-15 (In Russ.). https://doi.org/10.1716/optalma2017133511-15
  12. Alekberova ZS, Dubinina TV, Goloeva RG, Agafonova EM, Lila AM. Behcet’s disease concurrent with axial spondyloarthritis: the autors’ own observations. Nauchno-prakticheskaya revmatologiya. 2019;57(5):528-531. (In Russ.). https://doi.org/10.14412/1995-4484-2019-528-531
  13. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sacli FS, Erer B, Inoko H, Emrence Z, Cakar A, Abaci N, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epistasis between HLA-B51 and ERAP1. Nat Genet. 2013;45(2):202-207.  https://doi.org/10.1038/ng.2520
  14. Kang EH, Kim S, Park MY, Choi JY, Choi IA, Kim MJ, Ha YJ, Lee EY, Lee YJ, Lee EB, Kang C, Song YW. Behcet’s disease risk association fine-mapped on the IL23R-IL12RB2 intergenic region in Koreans. Arthritis Res Ther. 2017;19(1):227.  https://doi.org/10.1186/s13075-017-1435-5
  15. Castaño-Núñez Á, Montes-Cano MA, García-Lozano JR, Ortego-Centeno N, García-Hernández FJ, Espinosa G, Graña-Gil G, Sánchez-Bursón J, Juliá MR, Solans R, Blanco R, Barnosi-Marín AC, Gómez de la Torre R, Fanlo P, Rodríguez-Carballeira M, Rodríguez-Rodríguez L, et al. Association of Functional Polymorphisms of KIR3DL1/DS1 With Behcet’s Disease. Front Immunol. 2019;10:2755. https://doi.org/10.3389/fimmu.2019.02755
  16. Özgüçlü S, Duman T, Ateş FSÖ, Küçükşahin O, Çolak S, Ölmez Ü. Serum interleukin-37 level and interleukin-37 gene polymorphism in patients with Behcet disease. Clin Rheumatol. 2019;38(2):495-502.  https://doi.org/10.1007/s10067-018-4288-7
  17. Guedes MC, Borrego LM, Proença RD. Role of interleukin-17 in uveitis. Indian J Ophthalmol. 2016;64(9):628-634.  https://doi.org/10.4103/0301-4738.194339
  18. Sertoglu E, Omma A, Yucel C, Colak S, Sandikcl SC, Ozgurtas T. The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Behçet’s disease. Scand J Clin Lab Invest. 2018;78(6):443-449.  https://doi.org/10.1080/00365513.2018/1488179
  19. Cheng Y, Zhao X, Chen Y, Li Y, Jia R, Zhu L, Huang C, Sun X, Deng H, Li Z. Circulating immune complex analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behçet’s Disease. PLoS One. 2018;13(6):e0199047. https://doi.org/10.1371/journal pone. 0199047
  20. Prado LL, Goncalves CR, Viana VT, Saad CGS, Bonfa E. Anti-alpha-enolase antibodies in Behçet’s disease: a marker of mucocutaneous and articular disease activity? Clin Exp Rheumatol. 2018;36(6 suppl 115):28-32. 
  21. Lee SJ, Kang SE, Kang EH, Choi BY, Mazek-Hammersman K, Syed J, Zhan Y, Neff-Philip K, Park JK, et al. CXCL10/CXCR3 axis is associated with disease activity and the development of mucocutaneous lesions in patients with Behçet’s disease. Sci Rep. 2017;7:14720. https://doi.org/10.1038/s41598-017-15189-9
  22. Perazzio SF, Soeiro-Pereira PV, Dos Santos VC, de Brito MV, Salu B, Oliva MLU, Stevens AM, de Souza AVS, et al. Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease. Arthritis Res Ther. 2017;19:235.  https://doi.org/10.1186/s13075-017-1443-5
  23. Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behçet’s disease. Clin Exp Rheumatol. 2003;21(4 suppl 30):44-48. 
  24. Salmaninejad A, Zamani MR, Shabgah AG, Hosseini S, Mollael F, Hosseini N, Sahebkar A. Behcet’s Disease: An immunogenetic perspective. J Cel Phisiol. 2019;234960:8055-8074. https://doi.org/10.1002/jcp.27576
  25. De Menthon M, Lavalley MP, Madini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet’s disease a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287-1296. https://doi.org/10.1002/apt24642
  26. Kaya T. Genetics of Behcet’s Disease. Pathol Res Int. 2012;912589:6.  https://doi.org/10.1155/2012/912589
  27. Maldini C, Lavalley MP, Cheminant M, de Monton M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analises of observational studies. Rheumatology (Oxford). 2012;51(5):887-900.  https://doi.org/10.1093/rheumatology/ker 428
  28. Demirseren D, Ceyian G, Akoglu G, Emre S, Erten S, Armfn A, Metin A. HLA-B51 Subtypes in Turkish patients with Behcet’s disease and ther correlation with clinical manifestations. Cenet Mol Res. 2014;13(3):4788-4796. https://doi.org/10.4238/2014.july.28
  29. Davatchi F, Assaad-Khalil S, Calamia KT, Shahram F, Nadji A, Shams H, et al. The International Criteria for Behcet’s Disease (ISBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatology Venereol. 2014;28(3):338-347.  https://doi.org/10.1007/s10067-011-1694-5
  30. Davatchi F, Sadeghi Abdollahi B, Chams-Davatchi C, Shahram F, Shams H, Nadji A, Faezi T, et al. The saga of diagnostic classification criteria in Behcet’s disease. Int J Rheum Dis. 2015;18(6):594-605.  https://doi.org/10.1111/1756-185X.62520
  31. Kump II, Moeller KI, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA. Behcet’s disease: comparing 3 decades of response at the National Eye Institute. Can J Ophthalmol. 2008;43(4):468-472.  https://doi.org/10.3129/i08-080
  32. Alpsoy E, Donmez L, Bacanli A, Apaydin CS, Butun B. Review of the chronology of clinical manifestations in 60 patients with Behcet’s disease. Dermatology. 2003;207(4):354-356.  https://doi.org/10.1159/000074113
  33. Bas Y, Seckin HY, Kalkan G, Takci Z, Onder Y, Citil R, Demir S, Sahin S. Investigation of Behcet’s disease and recurrent aphthous stomatitis frequency the highest prevalence in Turkey. Balkan Med J. 2016;33(4):390-395.  https://doi.org/10.5152/balkanmedj.2016.15101
  34. Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007;48(4);573-585.  https://doi.org/10.3349/ymj.2007.48.4.573
  35. Ergun T, Gurbuz O, Dogusoy G, Mat C, Yazici H. Histopathologic features of the spontaneous pustular lesions of Behcet’s syndrome. Int J Dermatol. 1998;37(3):194-196.  https://doi.org/10.1046/j.1365-4362.1998.00276.x
  36. Kim B, LeBoit PE. Histopathologic features of erythema nodosum-like lesions in Behcet’s disease: a comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermotopathol. 2000;22(5):379-390.  https://doi.org/10.1097/00000372-200010000-00001
  37. Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term outcome gastrointestinal involvement in Behcet’s syndrome. Medicine (Baltimore). 2016;95(16):e3348. https://doi.org/10.1097/MD 0000000000003348
  38. Noel N, Bernard R, Wechsler B, Resche-Rigon V, Depaz P, Thi Huong Boutin D, et al. Long-term outcome of neuro-Behcet’s disease. Arthritis Rheum. 2014;66(5):1306-1314. https://doi.org/10.1002/art.38351
  39. Kidd D. Neurological complications of Behcet’s syndrome. J Neurol. 2017; 264(4 suppl 84):9.  https://doi.org/10.1007/s00415-017-8436-9
  40. Leiba M, Sefigsohn U, Sidi Y, Harats D, Sela BA, Griffin JH, Livneh A, Rosenberg N, Celenter I, Cur H, Ehrenfeld M. Thrombophilic factors are not the leading cause of thrombosis in Behcet’s disease. Ann Rheum Dis. 2004;63(11):1445-1449. https://doi.org/10.1136/ard.2003.014241
  41. Seyahi E, Yurdakul S. Behcet’s Syndrome and Thrombosis. Mediterr J Hematol Infect Dis. 2011;3(1):e2011026. https://doi.org/10.4084/MJHID.2011.026
  42. Ryu HJ, Seo MR, Choi HJ, Baek HS. Clinical Phenotypes of Korean patients with Behcet’s disease according to gender, age at onset, and HLA-B51. Korean J Intern Med. 2018;33(5):1025-1031. https://doi.org/10.3904/kjim 2016.202
  43. Yavus S, Akdeniz T, Hancez V, Bicakcidie M, Can M, Yanikkaya-Demirel G. Dual effects of testosterone in Behcet’s disease implications for the role in disease pathogenesis. Genes Immun. 2016;17(6):335-341.  https://doi.org/10.1038/gene.2016.28
  44. Ozdal PÇ. Behcet’s Uveitis: Current Diagnostic and Therapeutic Approach. Turk J Ophthalmol. 2020;50(3):169-182.  https://doi.org/10.4274/tjo.galenos.2019.60308
  45. Ozyazgan Y, Ucar D, Hatemi G, Yazici Y. Ocular Involvement of Behcet’s Syndrome: a Comprehensive Review. Clin Rev Allergy Immunol. 2015;49(3): 298-306.  https://doi.org/10.1007/s12016-014-8425-z
  46. Cunningham Et Jr, Tugal-Turkun I, Khairallah M, Okada A, Bodaghi B, Zeirhut M. Behcet’s Uveitis. Ocul Immunol Inflamm. 2017;25(1):2-6.  https://doi.org/10.1080/09273948.2017.1279840
  47. Ksiaa I, Abroug N, Kechida M, Zina S, Selliti B, Khochtali S, Attia S, Kharallah M. Eye and Behcet’s disease. J Fr Ophtalmol. 2019;42(6):626-641.  https://doi.org/10.1016/j.JFO.2018.09.027
  48. Tugal-Tutkun J, Ona S, Altan-Yaycioglu R, Altunbas HH, Urgahcioglu M. Uveitis in Behcet’s disease: analysis of 880 patients. Am J Ophthalmol. 2004; 138(3):373-380.  https://doi.org/10.1016/j.ajo 2004 03022
  49. Budzinskaya MV, Shelankova AV, Mikhaylova MA, Plyukhova AA, Nuriyeva NM, Fomin AV. Analisis of changes in central macular thickness based on optical coherence tomography angiography findings in retinal vein occlusion. Vestnik oftal’mologii. 2016;132(5):16-22 (In Russ.). https://doi.org/10/17116/oftalma2016132515-22
  50. Tugal-Tutkun I, Ozdal PC, Oray M, Onal S. Review for diagnostis of the year: Multimodal imaging Behcet’s uveitis. Ocul Immun Inflamm. 2017; 25(1):7-19.  https://doi.org/10.1080/09273948.2016.1205100
  51. Shpak NI. To a question of clinic and treatment of Behcet’s disease. Oftal’mologicheskiy zhurnal. 1977;(7):522-525 (In Russ.).
  52. Nugumanova AM, Samoilov AN. A clinical case of Behcet’s disease in practice of ophthalmologist. Prakticheskaya medicina. 2012;4(59):128-130. (In Russ.).
  53. Sheremet NL, Ronzina IA, Smirnova TV, Razumova IYu, Sheloudchenko VM. Optic Neuritis and Optic Ischemic Neuropathy: the Problem of Differential Diagnosis. Vestnic oftal’mologii. 2012;128(3):6-10. (In Russ.).
  54. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdazoglu S, Ogur V. A trial of azathioprine. Behcet’s syndrome. N Engl J Med. 1990;322(5):281-285.  https://doi.org/10.1056/NEJM.1990.o2013220509
  55. Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, Aktuna T, Pazarli A, Hamurgudan V, Muftuoglu. A. Low dose cyclosporin a versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76(4):241-243.  https://doi.org/10.1136/bjo.76.4.241
  56. Krasnov MM, Razumova IYu, Evseev NG, Polunin GS. Hemoperfusion in the treatment of autoimmune disease of the eyes. Vestnik oftal’mologii. 1987; (5):48-49. (In Russ.).
  57. Razumova IYu, Safonova TN, Komov VV, Fedorov AA. Extracorporeal Treatments for Some Autoimmune Eye Disease. Vestnik oftal’mologii. 2010; 126(3):21-25. (In Russ.).
  58. Razumova IYu, Sheremet NL, Komov VV. Hemoperfusion and plazmapheresis in the treatment of uveitis in various autoimmune diseases. In: «Vostok—Zapad». Sbornik nauchnykh trudov nauchno-prakticheskoy konferentsii po oftal’mologii s mezhdunarodnym uchastiyem [«East—West» Proceedings of the international Sientific Meeting]. Ufa. 2011;346-348. (In Russ.).
  59. Shelankova AV, Mihajlova MA, Andreeva IV, Savochkina OA, Budzinskaja MV. Efficacy of antiangiogenic therapy in patients with macular edema due to occlusion of a branch of the central retinal vein. Sovremennye tehnologii v oftal’mologii. 2015;3(5):184-186. (In Russ.).
  60. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recomendation for the use of antitumor necrosis factor biologic agents in patients with ocular inflammatory disoders. Ophthalmology. 2014;121:785-796e3. https://doi.org/10.1016/j.ophtha 2013.09.048
  61. Sfikakis PP, Theodossiadis P, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab in sight-treatening panuveitis in Behcet’s disease. Lancet. 2001;358(9278):295-296.  https://doi.org/10.1016/s0140-6736(01)05496-6
  62. Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int. 2011;31(2):243-245.  https://doi.org/10.1007/s00296-009-1178-y
  63. Diaz-Liopis M, Salom D, Garcia-de Vicuna C. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575-1581. https://doi.org/10.1016/j.ophtha2012.02.018
  64. Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimando O, Salvarani G, Lambert M, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease. Multicenter study of 124 patients. J Autoimmun. 2015;62:67-74.  https://doi.org/1016/j.jaut.2015.06.005
  65. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yochirani K, Inaba G. Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behchet disease with refractory uveoretinitis. J Rhem. 2004;31(7):1362-1368.
  66. Weichsler B, Sable-Fourtassou R, Bodaghi B. Infliximab in refractory uveitis due to Behcet’s disease. J Clin Exp Rheum. 2004;34:14-16. 
  67. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Liew SHM, Bezliak V, Fazia D. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777-787.  https://doi.org/10.1016/j.ophtha.2012.09.040
  68. Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191-197.  https://doi.org/10.1007/s10067-016-3506-4
  69. Tugal-Tutkun I, Pavesio C, De Cardoue A, Bernard-Poenaru O, Gul A. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized study and openlabel extension study. Ocul Immunol Inflamm. 2018;26(7):1023-1033. https://doi.org/10.1080/09273948.2017.1421233
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.